A tripeptide Diapin effectively lowers blood glucose levels in male type 2 diabetes mice by increasing blood levels of insulin and GLP-1.
The prevalence of type 2 diabetes (T2D) is rapidly increasing worldwide. Effective therapies, such as insulin and Glucagon-like peptide-1 (GLP-1), require injections, which are costly and result in less patient compliance. Here, we report the identification of a tripeptide with significant potential...
Guardado en:
| Autores principales: | , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2013
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/27103078f08840d5b187d6ab48190712 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:27103078f08840d5b187d6ab48190712 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:27103078f08840d5b187d6ab481907122021-11-18T08:40:09ZA tripeptide Diapin effectively lowers blood glucose levels in male type 2 diabetes mice by increasing blood levels of insulin and GLP-1.1932-620310.1371/journal.pone.0083509https://doaj.org/article/27103078f08840d5b187d6ab481907122013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24386218/?tool=EBIhttps://doaj.org/toc/1932-6203The prevalence of type 2 diabetes (T2D) is rapidly increasing worldwide. Effective therapies, such as insulin and Glucagon-like peptide-1 (GLP-1), require injections, which are costly and result in less patient compliance. Here, we report the identification of a tripeptide with significant potential to treat T2D. The peptide, referred to as Diapin, is comprised of three natural L-amino acids, GlyGlyLeu. Glucose tolerance tests showed that oral administration of Diapin effectively lowered blood glucose after oral glucose loading in both normal C57BL/6J mice and T2D mouse models, including KKay, db/db, ob/ob mice, and high fat diet-induced obesity/T2D mice. In addition, Diapin treatment significantly reduced casual blood glucose in KKay diabetic mice in a time-dependent manner without causing hypoglycemia. Furthermore, we found that plasma GLP-1 and insulin levels in diabetic models were significantly increased with Diapin treatment compared to that in the controls. In summary, our findings establish that a peptide with minimum of three amino acids can improve glucose homeostasis and Diapin shows promise as a novel pharmaceutical agent to treat patients with T2D through its dual effects on GLP-1 and insulin secretion.Jifeng ZhangChangyong XueTianqing ZhuAnuradha VivekanandanSubramaniam PennathurZhongmin Alex MaY Eugene ChenPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 12, p e83509 (2013) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Jifeng Zhang Changyong Xue Tianqing Zhu Anuradha Vivekanandan Subramaniam Pennathur Zhongmin Alex Ma Y Eugene Chen A tripeptide Diapin effectively lowers blood glucose levels in male type 2 diabetes mice by increasing blood levels of insulin and GLP-1. |
| description |
The prevalence of type 2 diabetes (T2D) is rapidly increasing worldwide. Effective therapies, such as insulin and Glucagon-like peptide-1 (GLP-1), require injections, which are costly and result in less patient compliance. Here, we report the identification of a tripeptide with significant potential to treat T2D. The peptide, referred to as Diapin, is comprised of three natural L-amino acids, GlyGlyLeu. Glucose tolerance tests showed that oral administration of Diapin effectively lowered blood glucose after oral glucose loading in both normal C57BL/6J mice and T2D mouse models, including KKay, db/db, ob/ob mice, and high fat diet-induced obesity/T2D mice. In addition, Diapin treatment significantly reduced casual blood glucose in KKay diabetic mice in a time-dependent manner without causing hypoglycemia. Furthermore, we found that plasma GLP-1 and insulin levels in diabetic models were significantly increased with Diapin treatment compared to that in the controls. In summary, our findings establish that a peptide with minimum of three amino acids can improve glucose homeostasis and Diapin shows promise as a novel pharmaceutical agent to treat patients with T2D through its dual effects on GLP-1 and insulin secretion. |
| format |
article |
| author |
Jifeng Zhang Changyong Xue Tianqing Zhu Anuradha Vivekanandan Subramaniam Pennathur Zhongmin Alex Ma Y Eugene Chen |
| author_facet |
Jifeng Zhang Changyong Xue Tianqing Zhu Anuradha Vivekanandan Subramaniam Pennathur Zhongmin Alex Ma Y Eugene Chen |
| author_sort |
Jifeng Zhang |
| title |
A tripeptide Diapin effectively lowers blood glucose levels in male type 2 diabetes mice by increasing blood levels of insulin and GLP-1. |
| title_short |
A tripeptide Diapin effectively lowers blood glucose levels in male type 2 diabetes mice by increasing blood levels of insulin and GLP-1. |
| title_full |
A tripeptide Diapin effectively lowers blood glucose levels in male type 2 diabetes mice by increasing blood levels of insulin and GLP-1. |
| title_fullStr |
A tripeptide Diapin effectively lowers blood glucose levels in male type 2 diabetes mice by increasing blood levels of insulin and GLP-1. |
| title_full_unstemmed |
A tripeptide Diapin effectively lowers blood glucose levels in male type 2 diabetes mice by increasing blood levels of insulin and GLP-1. |
| title_sort |
tripeptide diapin effectively lowers blood glucose levels in male type 2 diabetes mice by increasing blood levels of insulin and glp-1. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2013 |
| url |
https://doaj.org/article/27103078f08840d5b187d6ab48190712 |
| work_keys_str_mv |
AT jifengzhang atripeptidediapineffectivelylowersbloodglucoselevelsinmaletype2diabetesmicebyincreasingbloodlevelsofinsulinandglp1 AT changyongxue atripeptidediapineffectivelylowersbloodglucoselevelsinmaletype2diabetesmicebyincreasingbloodlevelsofinsulinandglp1 AT tianqingzhu atripeptidediapineffectivelylowersbloodglucoselevelsinmaletype2diabetesmicebyincreasingbloodlevelsofinsulinandglp1 AT anuradhavivekanandan atripeptidediapineffectivelylowersbloodglucoselevelsinmaletype2diabetesmicebyincreasingbloodlevelsofinsulinandglp1 AT subramaniampennathur atripeptidediapineffectivelylowersbloodglucoselevelsinmaletype2diabetesmicebyincreasingbloodlevelsofinsulinandglp1 AT zhongminalexma atripeptidediapineffectivelylowersbloodglucoselevelsinmaletype2diabetesmicebyincreasingbloodlevelsofinsulinandglp1 AT yeugenechen atripeptidediapineffectivelylowersbloodglucoselevelsinmaletype2diabetesmicebyincreasingbloodlevelsofinsulinandglp1 AT jifengzhang tripeptidediapineffectivelylowersbloodglucoselevelsinmaletype2diabetesmicebyincreasingbloodlevelsofinsulinandglp1 AT changyongxue tripeptidediapineffectivelylowersbloodglucoselevelsinmaletype2diabetesmicebyincreasingbloodlevelsofinsulinandglp1 AT tianqingzhu tripeptidediapineffectivelylowersbloodglucoselevelsinmaletype2diabetesmicebyincreasingbloodlevelsofinsulinandglp1 AT anuradhavivekanandan tripeptidediapineffectivelylowersbloodglucoselevelsinmaletype2diabetesmicebyincreasingbloodlevelsofinsulinandglp1 AT subramaniampennathur tripeptidediapineffectivelylowersbloodglucoselevelsinmaletype2diabetesmicebyincreasingbloodlevelsofinsulinandglp1 AT zhongminalexma tripeptidediapineffectivelylowersbloodglucoselevelsinmaletype2diabetesmicebyincreasingbloodlevelsofinsulinandglp1 AT yeugenechen tripeptidediapineffectivelylowersbloodglucoselevelsinmaletype2diabetesmicebyincreasingbloodlevelsofinsulinandglp1 |
| _version_ |
1718421488605855744 |